TABLE OF CONTENTS
Volume 8, Issue 2 (June 2005)
Editorial
Report from London FREE
R S Kirby
Prostate Cancer Prostatic Dis 8: 103; doi:10.1038/sj.pcan.4500807
Research Highlights
Prostate News FREE
Prostate Cancer Prostatic Dis 8: 104-107; doi:10.1038/sj.pcan.4500804
Reviews
The emerging role of the PI3-K-Akt pathway in prostate cancer progression FREE
L Li, M M Ittmann, G Ayala, M-J Tsai, R J Amato, T M Wheeler, B J Miles, D Kadmon and T C Thompson
Prostate Cancer Prostatic Dis 8: 108-118; advance online publication, February 22, 2005; doi:10.1038/sj.pcan.4500776
Wnt signalling and prostate cancer FREE
G W Yardy and S F Brewster
Prostate Cancer Prostatic Dis 8: 119-126; advance online publication, April 5, 2005; doi:10.1038/sj.pcan.4500794
Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade FREE
W A Woodward, P Wachsberger, R Burd and A P Dicker
Prostate Cancer Prostatic Dis 8: 127-132; advance online publication, January 11, 2005; doi:10.1038/sj.pcan.4500779
Nerve-sparing radical retropubic prostatectomy: techniques and clinical considerations FREE
P Gontero and R S Kirby
Prostate Cancer Prostatic Dis 8: 133-139; advance online publication, February 15, 2005; doi:10.1038/sj.pcan.4500781
Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer FREE
A V Kaisary
Prostate Cancer Prostatic Dis 8: 140-151; advance online publication, April 26, 2005; doi:10.1038/sj.pcan.4500800
Clinical ease of using doxazosin in BPH patients with and without hypertension FREE
W D Steers and R S Kirby
Prostate Cancer Prostatic Dis 8: 152-157; advance online publication, February 15, 2005; doi:10.1038/sj.pcan.4500787
Papers
PSA recurrence following radical prostatectomy is comparable for all age groups in the UK FREE
F A Khan, A V Kaisary, G B Boustead, D A Gillatt and M H Winkler
Prostate Cancer Prostatic Dis 8: 158-162; advance online publication, March 15, 2005; doi:10.1038/sj.pcan.4500786
Long-term outcome of detectable PSA levels after radical prostatectomy FREE
T E Ahlering and D W Skarecky
Prostate Cancer Prostatic Dis 8: 163-166; advance online publication, February 15, 2005; doi:10.1038/sj.pcan.4500788
What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate? FREE
M Kasibhatla, B Peterson and M S Anscher
Prostate Cancer Prostatic Dis 8: 167-173; advance online publication, February 15, 2005; doi:10.1038/sj.pcan.4500789
In vitro inhibition of angiogenesis by prostasomes FREE
G H Delves, A B Stewart, B A Lwaleed and A J Cooper
Prostate Cancer Prostatic Dis 8: 174-178; advance online publication, March 1, 2005; doi:10.1038/sj.pcan.4500790
The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer FREE
L Klotz, A Correia and W Zhang
Prostate Cancer Prostatic Dis 8: 179-183; advance online publication, April 5, 2005; doi:10.1038/sj.pcan.4500792
Sociodemographic factors associated with postprostatectomy radiotherapy FREE
T L Krupski, L Kwan and M S Litwin
Prostate Cancer Prostatic Dis 8: 184-188; advance online publication, April 5, 2005; doi:10.1038/sj.pcan.4500791
E-mail and oncology: a survey of radiation oncology patients and their attitudes to a new generation of health communication FREE
C Katzen, M J Solan and A P Dicker
Prostate Cancer Prostatic Dis 8: 189-193; advance online publication, April 26, 2005; doi:10.1038/sj.pcan.4500797
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme FREE
M Wirth, C Tyrrell, K Delaere, M Sánchez-Chapado, J Ramon, D M A Wallace, J Hetherington, F Pina, C Heyns, T Borchers, T Morris and J Armstrong on behalf of the 'Casodex' Early Prostate Cancer Trialists' Group
Prostate Cancer Prostatic Dis 8: 194-200; doi:10.1038/sj.pcan.4500799
